VolitionRx Limited develops epigenetics-based diagnostics through its Nucleosomics platform, which measures nucleosomes in blood and other bodily fluids. The company’s Nu.Q® product portfolio spans human diagnostics and monitoring for cancer, sepsis, trauma biomarker research and other disease areas, as well as veterinary oncology through Nu.Q® Vet assays.
VNRX news covers clinical publications and assay-development milestones, commercialization of Nu.Q® tests, veterinary cancer-test development, recombinant nucleosome products under rNuQ™, licensing and distribution activity, financial results, non-dilutive funding, equity financing and NYSE American listing-compliance matters. Volition’s research and development activities are centered in Belgium, with additional operations in the United States and London.
RedChip Companies will air interviews with Nexalin Technology (Nasdaq:NXL) and VolitionRX (NYSE American:VNRX) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, this Saturday, June 15, at 7 p.m. ET. Nexalin's CEO, Mark White, discusses their non-invasive neurostimulation technology for mental health conditions like insomnia, PTSD, and traumatic brain injuries. Volition's CEO, Cameron Reynolds, highlights their epigenetic markers for diagnostics, focusing on cancer and sepsis. Volition aims for cash flow neutrality by 2025 through non-dilutive funding, revenue growth, and cost reduction.
VolitionRx (NYSE AMERICAN: VNRX), a multi-national epigenetics firm, announced that its President and Group CEO, Cameron Reynolds, will present at the Jefferies Global Healthcare Conference in New York City on June 5, 2024, at 3:30 pm ET. The company aims to showcase its portfolio of patented epigenetic technologies for the early detection and monitoring of diseases such as sepsis and cancer. Investors are invited to schedule one-on-one meetings with the executive team by contacting investorrelations@volition.com.
VolitionRx (NYSE AMERICAN: VNRX) announced its Q1 2024 financial results and business update on May 13, 2024. Key highlights include $11.8 million in cash and cash equivalents, $170,000 in revenue (a 15% increase YoY), and ongoing cost reduction measures aiming for $10 million in annualized savings. The company is applying for $25 million in non-dilutive grants in the U.S. and $18 million in Europe. VolitionRx aims to achieve cash flow neutrality by 2025 through a mix of funding, revenue growth, and milestone payments. The company is focusing on commercializing its Nu.Q® NETs and Capture-PCR™ technologies, with new clinical data expected by the end of June 2024. A conference call to discuss these results is scheduled for May 14, 2024, at 8:30 a.m. U.S. Eastern Time.
VolitionRx (NYSE AMERICAN: VNRX) has scheduled a conference call on May 14, 2024, at 8:30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter 2024 and provide a business update. The call will be hosted by key executives and will include details on important events and upcoming milestones.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.